CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sam Chun Dang Pharm Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sam Chun Dang Pharm Co Ltd
71, Jeyakgongdan 2-gil, Hyangnam-eup
Phone: +82 220461100p:+82 220461100 HWASEONG, 18622  South Korea Ticker: 000250000250
Business Summary
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman Dae YinYoon 72 3/29/2022
President, Chief Executive Officer, Director Yin SeokJeon 48 3/29/2022 3/16/2018
Vice President Se YeongCheon 58
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 364 (As of 12/31/2015)
Outstanding Shares: 23,257,472 (As of 9/30/2024)
Shareholders: 28,295
Stock Exchange: KDQ
Fax Number: +82 220461101


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024